Anastasia Liapis, PhD
Founder, Acta Labs
Anastasia works on getting diagnostics out of the lab and into real-world use, and on how tests in clinics and in the field can also give early warning of new outbreaks. She is a geneticist by training (PhD, Icahn School of Medicine at Mount Sinai), with postdoctoral work in immunology at NYU.
At GNA Biosolutions, she was part of the leadership team that took an ultrafast point-of-care molecular diagnostics platform from early development through emergency authorization during COVID-19 and acquisition by HP Inc. She then helped establish and lead HP Health Solutions, a health technology incubation business spanning diagnostics, digital health and pandemic preparedness.
Through Acta Labs, she now advises on and develops diagnostics and detection technologies for pandemic preparedness, from point-of-care and distributed testing to sample preparation, new platform technologies and clinical metagenomics. She was previously an Entrepreneur in Residence at Ambitious Impact through its Founding to Give program, run in partnership with the School for Moral Ambition, and was supported by Catalyze Impact in developing her work in pandemic preparedness.